+

ES2166111T3 - Uso de tiagabina para el tratamiento de trastornos del sueño. - Google Patents

Uso de tiagabina para el tratamiento de trastornos del sueño.

Info

Publication number
ES2166111T3
ES2166111T3 ES98102356T ES98102356T ES2166111T3 ES 2166111 T3 ES2166111 T3 ES 2166111T3 ES 98102356 T ES98102356 T ES 98102356T ES 98102356 T ES98102356 T ES 98102356T ES 2166111 T3 ES2166111 T3 ES 2166111T3
Authority
ES
Spain
Prior art keywords
sleep disorders
tiagabine
treatment
alosteric
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98102356T
Other languages
English (en)
Inventor
Marike Lancel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7766768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2166111(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Application granted granted Critical
Publication of ES2166111T3 publication Critical patent/ES2166111T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

LA INVENCION TRATA DE UN PROCEDIMIENTO PARA TRATAR TRASTORNOS DEL SUEÑO EN UN PACIENTE QUE LO NECESITE, QUE INCLUYE LA ADMINISTRACION DE UNA CANTIDAD HIPNOTICAMENTE EFICAZ DE UN AGONISTA DE GABA A NO ALOSTERICO.
ES98102356T 1995-07-13 1996-07-10 Uso de tiagabina para el tratamiento de trastornos del sueño. Expired - Lifetime ES2166111T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19525598A DE19525598C2 (de) 1995-07-13 1995-07-13 Schlafmittel

Publications (1)

Publication Number Publication Date
ES2166111T3 true ES2166111T3 (es) 2002-04-01

Family

ID=7766768

Family Applications (3)

Application Number Title Priority Date Filing Date
ES96925704T Expired - Lifetime ES2165990T3 (es) 1995-07-13 1996-07-10 Thip para el tratamiento de trastornos del sueño.
ES98102355T Expired - Lifetime ES2166110T3 (es) 1995-07-13 1996-07-10 Agonistas no alostericos de gabaa para tratar trastornos del sueño.
ES98102356T Expired - Lifetime ES2166111T3 (es) 1995-07-13 1996-07-10 Uso de tiagabina para el tratamiento de trastornos del sueño.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES96925704T Expired - Lifetime ES2165990T3 (es) 1995-07-13 1996-07-10 Thip para el tratamiento de trastornos del sueño.
ES98102355T Expired - Lifetime ES2166110T3 (es) 1995-07-13 1996-07-10 Agonistas no alostericos de gabaa para tratar trastornos del sueño.

Country Status (12)

Country Link
US (1) US5929065A (es)
EP (3) EP0867178B1 (es)
JP (3) JP3754705B2 (es)
AT (3) ATE207349T1 (es)
AU (1) AU723954B2 (es)
CA (1) CA2226582C (es)
CL (1) CL2003002785A1 (es)
DE (4) DE19525598C2 (es)
DK (3) DK0867178T3 (es)
ES (3) ES2165990T3 (es)
PT (3) PT840601E (es)
WO (1) WO1997002813A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
JP2001511450A (ja) * 1997-08-01 2001-08-14 エラン コーポレーシヨン ピーエルシー チアガビンを含有する制御放出性の医薬組成物
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
AU7405000A (en) * 1999-09-28 2001-04-30 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
IL152770A0 (en) * 2000-06-26 2003-06-24 Warner Lambert Co Gabapentin analogues for sleep disorders
NZ547636A (en) * 2001-05-21 2008-03-28 Lundbeck & Co As H Process for preparing formulations comprising gaboxadol, anhydrous excipients using melt granulation with a non-aqueous binder
AU2004248890A1 (en) 2003-06-25 2004-12-29 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20070032553A1 (en) * 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
EP2343073A3 (en) * 2003-12-11 2011-10-12 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
TW200528098A (en) * 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
AU2004308962A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
ATE454140T1 (de) * 2004-02-18 2010-01-15 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
MXPA06011325A (es) * 2004-04-02 2006-12-15 Lundbeck & Co As H Tratamiento de la funcion respiratoria alterada con gaboxadol.
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
US8022084B2 (en) 2005-01-28 2011-09-20 H. Lundbeck A/S Polymorphic forms of a GABAA agonist
JP5380930B2 (ja) * 2007-07-24 2014-01-08 大正製薬株式会社 睡眠改善剤
SMT202100340T1 (it) * 2014-06-06 2021-07-12 Ovid Therapeutics Inc Metodi per aumentare l'inibizione tonica e trattare l'insonnia secondaria
PT3274331T (pt) 2015-03-24 2020-04-02 H Lundbeck As Fabrico de 4,5,6,7-tetra-hidroisoxazolo[5,4-c]- piridin-3-ol
WO2017015049A1 (en) 2015-07-17 2017-01-26 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
BR112019002538A2 (pt) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
JP2022514194A (ja) 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
US11986714B2 (en) 2018-12-14 2024-05-21 Raimondo Fazio Martial arts training device
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
MX2022007715A (es) 2019-12-18 2022-07-19 Ovid Therapeutics Inc Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.
TW202208373A (zh) 2020-05-20 2022-03-01 美商瑟泰戈治療學股份有限公司 環經氘化之加波沙朵及其用於治療精神病症用途
KR102773472B1 (ko) * 2021-05-21 2025-02-27 한국식품연구원 구릿대 추출물을 유효성분으로 포함하는 수면장애 또는 불면증의 예방, 개선 또는 치료용 조성물
WO2023015395A1 (en) * 2021-08-11 2023-02-16 Psyched Wellness Ltd. Amanita muscaria extracts and compounds and their beneficial and therapeutic use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4786647A (en) * 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5185446A (en) * 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
DK58291D0 (da) * 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
US6077839A (en) * 1992-03-19 2000-06-20 Allergan Sales, Inc. Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists

Also Published As

Publication number Publication date
DE19525598C2 (de) 1997-09-25
EP0840601B1 (en) 2001-10-24
AU723954B2 (en) 2000-09-07
ES2166110T3 (es) 2002-04-01
DE19525598A1 (de) 1997-01-16
CA2226582A1 (en) 1997-01-30
DE69616376D1 (de) 2001-11-29
EP0867184B1 (en) 2001-10-24
JP2009057382A (ja) 2009-03-19
PT840601E (pt) 2002-04-29
DK0840601T3 (da) 2002-02-18
DE69616375T2 (de) 2002-07-11
WO1997002813A1 (en) 1997-01-30
DE69616333D1 (de) 2001-11-29
DK0867178T3 (da) 2002-02-18
PT867178E (pt) 2002-04-29
JP3754705B2 (ja) 2006-03-15
ES2165990T3 (es) 2002-04-01
CA2226582C (en) 2008-02-19
DK0867184T3 (da) 2002-02-18
EP0867178A1 (en) 1998-09-30
EP0867178B1 (en) 2001-10-24
EP0867184A1 (en) 1998-09-30
PT867184E (pt) 2002-04-29
US5929065A (en) 1999-07-27
ATE207356T1 (de) 2001-11-15
AU6613796A (en) 1997-02-10
ATE207352T1 (de) 2001-11-15
JPH11509194A (ja) 1999-08-17
ATE207349T1 (de) 2001-11-15
JP2005047925A (ja) 2005-02-24
DE69616333T2 (de) 2002-07-04
EP0840601A1 (en) 1998-05-13
CL2003002785A1 (es) 2005-04-08
DE69616376T2 (de) 2002-06-27
DE69616375D1 (de) 2001-11-29

Similar Documents

Publication Publication Date Title
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
BR0213358A (pt) Uso de flibanserina
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
ES2187659T3 (es) Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.
ES2074565T3 (es) Empleo de melatonina para tratar el sindrome pre-menstrual.
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ES2174337T3 (es) Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular.
IT1282736B1 (it) Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
IL156798A0 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependency
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
DK1077683T3 (da) Antidepressiv behandling
EE05559B1 (et) IL6R/IL6 kim„„ri kasutamine ravimi valmistamiseks, mis on ette n„htud neuroloogiliste haiguste ja h„irete ravimiseks ja/v?i v„ltimiseks
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
ES2188742T3 (es) Trapidil para uso en la terapia de cuadros patologicos influenciables por la inmunomodulacion.
CO5590922A2 (es) Uso de istradefilina (kw-6002) para el tratamiento de trastornos de la conducta
BR0314364A (pt) Uso de inibidores de pde iv para tratar angiogênese
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 867184

Country of ref document: ES

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载